Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Brand Name : BC LisPram
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 29, 2021
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pramlintide,Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.
Brand Name : PramExe
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 26, 2021
Lead Product(s) : Pramlintide,Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pramlintide,Insulin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XP-3924 resulted in 62% reduction of hyperglycemia after a glucose challenge. XP-3924 showed promising glucose control when compared to both Humulin R and co-administered injections of Humulin R & Symlin and it showed improved glucose control when compar...
Brand Name : Xerisol
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 18, 2020
Lead Product(s) : Pramlintide,Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?